Academic Journal
Q2Current Problems in Cancer
About Current Problems in Cancer
About Current Problems in Cancer
Current Problems in Cancer is a peer-reviewed scholarly journal published by Elsevier B.V. (United States). It focuses on Q2. Publication coverage spans 1976-2026.
Key indicators: ISSN 0147-0272, 1535-6345; H-index 54.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (54): Strong citation impact — 54 articles cited at least 54 times each, reflecting solid influence.
Publishing in Current Problems in Cancer
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q2. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Current Problems in Cancer?
0147-0272, 1535-6345.
Who publishes Current Problems in Cancer?
Elsevier B.V..
What are Current Problems in Cancer's metrics?
H-index 54.
Is Current Problems in Cancer peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Diverse Scientific and Economic Studies; Ferroelectric and Negative Capacitance Devices; Human auditory perception and evaluation; Educational Robotics and Engineering; Big Data and Digital Economy; Lung Cancer Treatments and Mutations.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
3,740.00 USD; 3,500.00 EUR; 2,990.00 GBP; 463,870.00 JPY
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Reflection of patient-reported anxiety via ePRO in routine pharmacist documentation during cancer chemotherapy: A paired analysis with sensitivity analyses
Yuki Takei, Atsufumi Nomoto, Mizuki Kawashima, Yuko Miyake et al.
2026-12 · DOI: 10.1016/j.currproblcancer.2026.101349Current molecular targeting in solid tumors: Progress and perspectives
Yogesh Murti, Krishn K. Agrawal, Alok N. Sharma
2026-12 · DOI: 10.1016/j.currproblcancer.2026.101347Salvage outcomes with teclistamab after BCMA-directed therapy failure in relapsed/refractory multiple myeloma: a systematic review and meta-analysis
Hamzeh T. Al-Momany, Dani Zaid Kaylani, Omar Abuhashem, Abdallah Adel Nofal et al.
2026-12 · DOI: 10.1016/j.currproblcancer.2026.101343Predictors of change in cognitive function for patients with cancer treated with allogeneic hematopoietic cell transplant
Megha Jacob, Matthew A. Bergens, Matthew Braun, Ernaya J. Johnson et al.
2026-12 · DOI: 10.1016/j.currproblcancer.2026.101334Unraveling lung cancer complexity: Spatial omics in tumor microenvironment characterization and precision medicine
Sanjukta Dasgupta, Subhayan Das, Shouvik Saha
2026-12 · DOI: 10.1016/j.currproblcancer.2026.101333Information for Readers
2026-10 · DOI: 10.1016/s0147-0272(26)00072-3Table of Contents
2026-10 · DOI: 10.1016/s0147-0272(26)00073-5Experience of the implementation of a lung cancer screening program at the Hospital General de Catalunya (Barcelona, Spain)
Irene Moya-Horno, Adrián González-Marrón, Paula Barcos-Muñoz, Santiago Abad et al.
2026-10 · DOI: 10.1016/j.currproblcancer.2026.101329Blinatumomab versus chemotherapy in pediatric B-ALL: A meta-analysis of randomized trials in relapsed and high-risk frontline disease
Adeena Musheer, Muhammad Shaheer Mannan, Muhammad Waqas Khan, Ayesha Junaid et al.
2026-10 · DOI: 10.1016/j.currproblcancer.2026.101328Multicenter retrospective study on the clinical profiles of patients with extensive-stage small-cell lung cancer who met the eligibility criteria for clinical trials
Tatsuya Yazaki, Kei Sonehara, Toshiharu Tsutsui, Shuhei Nozawa et al.
2026-10 · DOI: 10.1016/j.currproblcancer.2026.101327Title Page
2026-10 · DOI: 10.1016/s0147-0272(26)00071-1Clinicopathological profile and treatment outcomes of advanced/unresectable thymic malignancies from a tertiary care centre in India
Swasthik Upadhya, Jayashimman Vasanthraman, Aparna Sharma, Sachin Khurana et al.
2026-10 · DOI: 10.1016/j.currproblcancer.2026.101330Intraductal papillary mucinous neoplasms: a comprehensive analysis combining genetic, immunopathological and clinical management
Giovanni Izzo, Pietro Tralongo, Marina Cerreto, Gabriele Ricciardi et al.
2026-10 · DOI: 10.1016/j.currproblcancer.2026.101332Spatial transcriptomics of primary and metastatic ALK-rearranged NSCLC reveals site-specific adaptations
Warisa Khatoon, Kaustar Yadav, Amit Katiyar, Sunil Kumar et al.
2026-10 · DOI: 10.1016/j.currproblcancer.2026.101331Table of Contents
2026-08 · DOI: 10.1016/s0147-0272(26)00057-7Artificial intelligence, omics, and biomarkers: Redefining lung cancer early detection
Anam Nizam, Nawal Shireen, Mohd Rahil Hasan, Saumitra Singh et al.
2026-08 · DOI: 10.1016/j.currproblcancer.2026.101312Advancements and perspectives of neoadjuvant immunotherapy in resectable non-small cell lung cancer
Aparna Sharma, Praful Pandey, Swasthik Upadhya, Deepam Pushpam et al.
2026-08 · DOI: 10.1016/j.currproblcancer.2026.101311Information for Readers
2026-08 · DOI: 10.1016/s0147-0272(26)00056-5Too late to fall: Time to PSA nadir and early oncologic failure after cryotherapy and high-intensity focused ultrasound for localized prostate cancer
Umberto Anceschi, Salvatore Basile, Leonardo Misuraca, Riccardo Mastroianni et al.
2026-08 · DOI: 10.1016/j.currproblcancer.2026.101314Clinical impact of a single time-point protocol paired FDG-PET and radioactive iodine scan for comprehensive disease assessment in differentiated thyroid cancer
Margaret Locke, Charit Taneja, Mehdi Djekidel, Nagashree Seetharamu et al.
2026-08 · DOI: 10.1016/j.currproblcancer.2026.101315Reviews
Community Reviews
Version History
October 9, 2026 at 10:19 pm
October 2, 2026